A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012 [Studio clinico di fase II a singolo braccio di trattamento con tremelimumab, un anticorpo monoclonale umano, in monoterapia in pazienti con mesotelioma maligno non resecabile. Codice dello Studio]

Trial Profile

A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012 [Studio clinico di fase II a singolo braccio di trattamento con tremelimumab, un anticorpo monoclonale umano, in monoterapia in pazienti con mesotelioma maligno non resecabile. Codice dello Studio]

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Mesothelioma
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 09 Apr 2014 Pooled pharmacokinetic analysis presented at the 105th Annual Meeting of the American Association for Cancer Research.
    • 11 Aug 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2012-002762-12).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top